Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop small-molecule drugs through AI to treat obesity and other cardiometabolic diseases.

The grandmother of Lilly Sullivan and Jack Sullivan, two children who have been missing from Nova Scotia since May 2, called for a public inquiry into their disappearance. Belynda Gray, the children's paternal grandmother, said she believed warning signs may have been missed in an interview with The Globe and Mail.

The Boston-based AI/ML startup focuses on endocrine and cardiometabolic diseases and will use that expertise to generate new small molecule obesity medications for Lilly.

(Reuters) -Superluminal Medicines said on Thursday it had signed a deal with U.S. drugmaker Eli Lilly worth up to $1.3 billion to discover and develop obesity drugs. The deal will give Lilly access to Superluminal's proprietary platform to discover drug targets related to cardiometabolic diseases and obesity.

Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced return prospects. See more.

As Trump has pressured drugmakers to lower the cost of medicines in the U.S., the pharma industry has coalesced behind a message of rebalancing what nations pay to better reflect the innovation and value of drugmaking.

Eli Lilly (LLY) recently faced legal challenges as Texas Attorney General Ken Paxton filed a lawsuit against the company, accusing it of bribery and inducement, which might weigh heavily on its reputation.

Eli Lilly insiders made notable stock purchases in August, but competitive pressures and pricing risks make me question its investment appeal. Read the full stock analysis here.